TOOLS FOR INSERTIONAL MUTAGENESIS IN THE MOUSE
Release Date: January 25, 2001
RFA: RFA-DA-01-011
National Institute on Drug Abuse
(http://www.nida.nih.gov)
National Institute on Aging
(http://www.nih.gov/nia/)
National Institute of Mental Health
(http://www.nimh.nih.gov)
National Institute of Dental and Craniofacial Research
(http://www.nidcr.nih.gov)
National Eye Institute
(http://www.nei.nih.gov)
National Institute on Deafness and Other Communication Disorders
(http://www.nidcd.nih.gov)
National Human Genome Research Institute
(http://www.nhgri.nih.gov)
National Institute of Diabetes and Digestive and Kidney Diseases
(http://www.niddk.nih.gov)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
(http://www.nih.gov/niams)
National Institute of Allergy and Infectious Diseases
(http://www.niaid.nih.gov)
National Institute of Neurological Disorders and Stroke
(http://www.ninds.nih.gov)
Letter of Intent Receipt Date: March 11, 2001
Application Receipt Date: April 11, 2001
THIS REQUEST FOR APPLICATIONS (RFA) USES THE MODULAR GRANT AND JUST-
IN-TIME CONCEPTS. IT INCLUDES DETAILED MODIFICATIONS TO STANDARD
APPLICATION INSTRUCTIONS THAT MUST BE USED WHEN PREPARING APPLICATIONS
IN RESPONSE TO THIS RFA.
PURPOSE
This RFA solicits proposals for development of tools and techniques for
the establishment of random and targeted sequence-tagged insertion
libraries of embryonic stem (ES) cells that can be used to generate
mutant mice in which the expression of the tagged gene could be
controlled temporally and spatially. The development of such a
resource for wide distribution to the scientific community would make
it possible to scan the sequence database for any gene of interest and
order the corresponding targeted ES cell line. Ideally, the
insertional mutagenesis system developed would permit a wide range of
genetic analyses and manipulations, including enhancer-trapping,
conditional knockouts, conditional expression or overexpression, etc.
It also would permit the larger community of investigators to utilize
genomic resources efficiently.
This effort complements ongoing National Institutes of Health (NIH)
efforts to create and characterize induced point mutations in mice
using ethylnitrosourea (ENU) and provides a functional genomics tool to
translate the information from the Mouse Genome Sequencing Project.
Further information about NIH initiatives on mouse genomics and
genetics resources is available at http://www.nih.gov/science/mouse.
This initiative will utilize the research project grant (R01) and
exploratory/development grant (R21) mechanisms. It will be run in
parallel with a program of identical scientific scope that uses the
Small Business Innovation Research/Small Business Technology Transfer
Research (SBIR/STTR) programs
(http://grants.nih.gov/grants/funding/sbirsttr1/index.pdf).
HEALTHY PEOPLE 2010
The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2010," a
PHS-led national activity for setting priority areas. This RFA, "Tools
for Insertional Mutagenesis in the Mouse," is related to one or more of
the priority areas. Potential applicants may obtain a copy of "Healthy
People 2010" at http://www.health.gov/healthypeople/.
ELIGIBILITY REQUIREMENTS
Applications may be submitted by domestic and foreign, for-profit and
non-profit organizations, public and private, such as universities,
colleges, hospitals, laboratories, units of state and local
governments, and eligible agencies of the federal government.
Racial/ethnic minority individuals, women, and persons with
disabilities are encouraged to apply as Principal Investigators.
MECHANISM OF SUPPORT
This RFA will use the NIH research project grant (R01) and
exploratory/developmental grant (R21). Applicants are advised to
contact the appropriate Institute program staff listed under INQUIRIES
for additional information and specific application procedures.
For research in methods development, the R21 mechanism is particularly
appropriate. The R21 mechanism is intended to encourage exploratory
research projects with sound methodology and strong rationales in
underdeveloped research areas, such as those covered in this RFA. All
applicants must use the NIDA R21 Guideline at
http://grants.nih.gov/grants/guide/pa-files/PA-01-012.html. The R21 is
limited to $100,000 maximum direct costs per year for up to three
years. Investigators may also choose to include methods development as
one component within the R01 mechanism.
Responsibility for the planning, direction, and execution of the
proposed project will be solely that of the applicant. The total
project period for an application submitted in response to this RFA may
not exceed three years. This RFA is a one-time solicitation. Future
new or competing continuation applications will compete with all
investigator-initiated applications and be referred and reviewed
according to the customary peer review procedures.
This RFA is the result of a trans-NIH initiative, and awards will be
made through the
institute whose mission is most closely related to the proposed work.
The earliest anticipated award date is September 30, 2001.
FUNDS AVAILABLE
The participating institutes intend to commit approximately $2.8
million in total costs [direct plus Facilities and Administrative (F &
A) costs] in FY 2001 to fund six to eight new grants in response to
this RFA. An applicant may request a project period of up to three
years. For R01 grants, an applicant may request a budget for direct
costs of up to $250,000 per year, including F & A costs on consortium
arrangements. For an exploratory/development grant (R21), an applicant
may request a budget for direct costs of up to $100,000 per year,
including F & A costs on consortium arrangements. Because the nature
and scope of the research proposed may vary, it is anticipated that the
size of awards also will vary. Although the financial plans of the
participating institutes provide support for this program, awards
pursuant to this RFA are contingent upon the availability of funds and
the receipt of a sufficient number of meritorious applications.
RESEARCH OBJECTIVES
Background
The use of transposon tagging and retroviral insertional mutagenesis in
model organisms such as Drosophila, C. elegans, and zebrafish has
greatly facilitated the characterization of gene function and permitted
rapid cloning of the mutated gene. This approach has complemented
analysis of gene function using chemically and X-ray-induced mutations
where great effort is expended in positional cloning of the mutant
gene. Insertional mutagenesis in mice is made practical by the
availability of efficient methods of transfecting ES cells, the
production of a 2.5 to 3.5X draft of the mouse genome using C57BL/6
mouse strain by February 2001, polymerase chain reaction (PCR), and
automated sequencing methods.
The development of both random and targeted sequence-tagged insertion
libraries in mouse ES cells would greatly facilitate analysis of gene
function in mice and permit the rapid development of mouse models for
human genetic disease. Not only would such an approach create an
induced mutation resource, but it would also permit analysis of
patterns of gene expression. The value of this resource would be
greatly enhanced by the use of site-specific gene recombination systems
or trans-acting factor binding sites that would allow the expression of
the tagged gene to be controlled temporally and spatially.
There are two recombination systems currently used to create
conditional mutations or knockouts in mice are the cre-lox and FLP-FRT
site-specific recombination systems. The usefulness of these
recombination systems in vertebrate systems is dependent on the
activity of the recombinase and the ability to drive the expression of
the recombinase with non-mammalian promoters, such as ecdysone or
tetracycline sensitive promoters. The ability to control the spatial
expressions of the recombinase is limited by the lack of well-
characterized enhancers that control gene expression. To overcome
these obstacles, modifications of these recombinase systems, as well as
the development of new ones, are needed. In addition, the flexibility
of existing systems can be enhanced through the use of inducible
promoters or fusion protein recombinases that are activated by ligands
such as steroids.
The creation of appropriate insertional mutagenesis vectors containing
site-specific recombination targets will also aid in the generation of
chromosomal deletions, duplications, and inversions when another
genetic locus is tagged with a vector containing the same target
sequence. Chromosomal aberrations are an important tool for selecting
and mapping mutations in a specific chromosomal region and for
positional cloning, as well as for the study of position effects and
contiguous gene syndromes. In addition, inversions can be combined to
produce balancer chromosomes. Balancer chromosomes carrying dominant
phenotypic markers simplify the maintenance of recessive mutations and
combinations of alleles from generation to generation because the
balancer prevents recombination. Balancer chromosomes also facilitate
isolation and high-throughput screening for new recessive mutations.
Current estimates are that a total of 500,000 ES cell lines may be
needed to tag every single mouse gene. Thus high-throughput methods
are needed to automate the processing of large numbers of clones and to
identify the site of insertion.
The use of C57BL/6 ES cells will speed the distribution of mice in a
defined isogenic background by eliminating the need to cross sv129 mice
over successive generations into C57BL/6. Many of the current sv129
cell lines in use are derived from different strains of sv129 mice,
making comparisons among the various targeted mutations difficult until
transferred to a defined genetic background. Moreover, much of the
public chemical mutagenesis and sequencing effort is being done in
C57BL/6. Thus, crosses between mutations created by ENU in C57BL/6 and
C57BL/6 carrying a targeted deletion can be performed in a single
generation without concern about the effects of genetic background.
It is anticipated that the results of funded research projects will
eventually lead to production of new complete libraries of ES cells
with random or targeted insertional mutations for wide distribution to
the research community.
Examples of research that may be considered responsive to this RFA
include, but are not limited to, those listed below.
o Feasibility studies for the establishment of sequence-tagged
insertional libraries of C57BL/6 ES cells in which the expression of
the tagged gene can be controlled temporally and spatially.
o The development of new or modified site-specific recombination
systems for efficient random and targeted insertional mutagenesis and
enhanced control of conditional expression.
o The development of novel vectors that allow imaging of specific cell
types or tissues, metabolic activity, or other cellular or
physiological functions.
o The invention of efficient systems for transposon tagging in
mammalian systems for the wide use of the scientific community.
o The development of vectors for identification ("trapping") of
promoters and enhancers that could be used for tissue-specific and
temporal expression of recombinases and for the study of gene
expression patterns.
o Methods to automate the processing of large numbers of clones and to
identify the sites of insertion.
SPECIAL REQUIREMENTS
Restricted availability of unique research resources upon which further
studies are dependent can impede the advancement of research and
delivery of medical care. The sharing of biomaterials, data, and
software in a timely manner, on the other hand, has been an essential
element in the rapid progress that has been made in the genetic
analysis of mammalian genomes. NIH policy requires investigators to
make unique research resources readily available for research purposes
to qualified individuals within the scientific community when they have
been published [NIH Grants Policy Statement
(http://grants.nih.gov/grants/policy/nihgps), Principles and Guidelines
for Recipients of NIH Research Grants and Contracts on Obtaining and
Disseminating Biomedical Research Resources: Final Notice, December
1999 (http://www.nih.gov/od/ott/RTguide_final.htm)]. Biomaterials and
other patentable research resources (e.g., mutagenesis protocols,
vectors, embryonic cell lines, etc.) produced in projects funded by
this RFA are expected to be made available and distributed to the
broader scientific community.
The NIH is interested in ensuring that the research resources developed
through this RFA become readily available to the research community for
further research, development, and application, in the expectation that
this will lead to products and knowledge of benefit to the public. For
this reason, NIH is concerned that patents on the vectors, mutagenesis
methods, cell lines, and other research resources might have a chilling
effect on the future development of products and information that may
improve the public health. At the same time, NIH recognizes the rights
of grantees to elect and retain title to subject inventions developed
under federal funding under the provision of the Bayh-Dole Act.
There are two special requirements for this RFA regarding research
resources produced in proposed projects:
(1) Applicants are required to include in their application a specific
plan by which they will share research resources with the wider
scientific community.
(2) Applicants are required to include a plan addressing if, or how,
they will exercise their intellectual property rights while making
available to the broader scientific community patentable research
resources. These plans should be consistent with the policies of their
institutional offices of technology transfer.
Applicants are encouraged to discuss their proposed plans for
addressing these requirements with their institutional offices of
technology transfer. Each of the two requirements is discussed in
detail below.
Plan to Share Research Resources
To address the joint interests of the government in the availability
of, and access to, the results of publicly funded research, NIH
requires applicants who respond to this RFA to propose detailed plans
for sharing the research resources generated through the grant. It is
expected that the resources to be shared include all materials
developed in projects funded under the RFA, including but not limited
to, the following: vectors, high-throughput methods for identifying
insertion sites, mutagenesis protocols, and cell lines. A reasonable
time frame for release of materials should be specified in the
application and will be considered during the review of the plan for
sharing.
It is expected that the investigator"s data and biomaterials sharing
plan will include the access to biomaterials and methods not currently
available to the wider scientific community.
The scientific review group will evaluate the adequacy of the proposed
plan for sharing and data access. Comments on the plan and any concerns
will be presented in an administrative note in the Summary Statement.
The adequacy of the plan will be considered by NIH program staff and
will be important in determining whether the grant shall be awarded.
The sharing plan as approved, after negotiation with the applicant when
necessary, will be a condition of the award. Evaluation of non-
competing continuation applications will include assessment of the
effectiveness of research resource release.
Intellectual Property Rights
NIH is interested in ensuring that the research resources developed
through this RFA become readily available to the research community.
With regard to patentable research results, such as mutagenesis
protocols, methodologies, cell lines, and vectors, the NIH requires
applicants who respond to this RFA to develop a plan addressing if, or
how, they will exercise their intellectual property rights while making
available to the broader scientific community research resources
produced in projects funded under this RFA. This is expected to
include an elaboration of the applicant"s anticipated plans to
generate, or not generate, patents and/or exclusive or non-exclusive
licensing of biomaterials and other patentable subject matter created
in projects funded under this RFA. This plan should be consistent with
the applicant"s institution"s policies on intellectual property rights.
This plan is also expected to include disclosure of any pre-existing
agreements involving intellectual property rights, including options to
for-profit research sponsors that are associated with biomaterials and
data that may be generated. The requirement for this plan is in
addition to the requirement for the plan for sharing and disseminating
research resources described in the previous section.
The majority of transfers to not-for-profit entities should be
implemented under terms no more restrictive than the Uniform Biological
Materials Transfer Agreement (UBMTA). In particular, recipients are
expected to use the Simple Letter Agreement provided at
http://www.nih.gov/od/ott/RTguide_final.htm, or another document with
no more restrictive terms, to readily transfer unpatented tools
developed with NIH funds to other recipients for use in NIH-funded
projects. If the materials are patented or licensed to an exclusive
provider, other arrangements may be used, but commercialization option
rights, royalty reach-through, or product reach-through rights back to
the provider are inappropriate.
Similarly, when for-profit entities are seeking access to NIH-funded
tools for internal use purposes, recipients should ensure that the
tools are transferred with the fewest encumbrances possible. The
Simple Letter Agreement may be expanded for use in transferring tools
to for-profit entities, or simple internal use license agreements with
execution or annual use fees may be appropriate.
The scientific review group will evaluate the adequacy of the proposed
plan for handling intellectual property rights. Comments on the plan
and any concerns will be presented in an administrative note in the
Summary Statement. The adequacy of the proposed plan will be
considered by NIH program staff in determining whether the grant shall
be awarded. The plan as approved, after negotiation with the applicant
when necessary, will be a condition of the award. Evaluation of non-
competing continuation applications will include assessment of the
awardee’s adherence to the proposed plan.
Applicants also are reminded that the grantee institution is required
to disclose each subject invention to NIH within two months after the
inventor discloses it in writing to grantee institutional personnel
responsible for patent matters. The awarding institute reserves the
right to monitor awardee activity in this area to ascertain if patents
or patent applications on mutagenesis protocols, cell lines, vectors,
or other patentable subject matter are adversely affecting the goals of
this RFA.
Principles and guidelines for recipients of NIH research grants on
obtaining and disseminating biomedical research resources can be found
at http://www.nih.gov/od/ott/RTguide_final.htm.
Post-Award Management
During the course of the award period, the Principal Investigator may
be invited to meet with NIH staff to review and share scientific
progress. Other scientists external to and knowledgeable about these
studies also may be invited to participate. Application budget
requests should include travel funds for the Principal Investigator to
attend annual meetings in the metropolitan Washington, D.C., area.
URLS IN NIH GRANT APPLICATIONS OR APPENDICES
All applications and proposals for NIH funding must be self-contained
within specified page limitations. Unless otherwise specified in an
NIH solicitation, Internet addresses (URLs) should not be used to
provide information necessary to the review because reviewers are under
no obligation to view the Internet sites. Reviewers are cautioned that
their anonymity may be compromised when they directly access an
Internet site.
LETTER OF INTENT
Prospective applicants are asked to submit a letter of intent that
includes a descriptive title of the overall proposed research, the
name, address and phone number of the Principal Investigator, and the
number and title of this RFA. In addition, the letter of intent should
identify all other personnel who will be involved in the research and
their institutions. Although the letter of intent is not required, is
not binding, does not commit the sender to submit an application, and
does not enter into the review of subsequent applications, the
information that it contains allows NIH staff to estimate the potential
review workload and to plan for the review.
The letter of intent is to be sent to:
Jonathan D. Pollock, Ph.D.
Division of Neuroscience and Behavioral Research
National Institute on Drug Abuse/NIH
6001 Executive Boulevard, Room 4284, MSC 9555
Bethesda, MD 20892-9555
Phone: (301) 443-6300
Fax: (301) 594-6043
APPLICATION PROCEDURES
The research grant application form PHS 398 (rev. 4/98) is to be used
in applying for these grants. Application kits are available at most
institutional offices of sponsored research and may be obtained from
the Division of Extramural Outreach and Information Resources, National
Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD
20892-7910, Phone (301) 710-0267, E-mail: GrantsInfo@nih.gov.
SPECIFIC APPLICATION INSTRUCTIONS FOR MODULAR GRANTS
The modular grant concept establishes specific modules in which direct
costs may be requested, as well as a maximum level for requested
budgets. Only limited budgetary information is required under this
approach. The just-in-time concept allows applicants to submit certain
information only when there is a possibility for an award. It is
anticipated that these changes will reduce the administrative burden
for the applicants, reviewers, and institute staff. The research grant
application form PHS 398 (rev. 4/98) is to be used in applying for
these grants, with the modifications noted below.
BUDGET INSTRUCTIONS
Modular Grant applications will request direct costs in $25,000
modules, up to a total direct cost request of $250,000 per year. The
total direct costs must be requested in accordance with the program
guidelines and the modifications made to the standard PHS 398
application instructions described below:
PHS 398
o FACE PAGE - Items 7a and 7b should be completed, indicating Direct
Costs (in $25,000 increments up to a maximum of $250,000) and Total
Costs [Modular Total Direct plus Facilities and Administrative (F&A)
costs] for the initial budget period. Items 8a and 8b should be
completed indicating the Direct and Total Costs for the entire proposed
period of support.
o DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD - Do not complete Form
Page 4 of the PHS 398. It is not required and will not be accepted
with the application.
o BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT - Do not complete
the categorical budget table on Form Page 5 of the PHS 398. It is not
required and will not be accepted with the application.
o NARRATIVE BUDGET JUSTIFICATION - Prepare a Modular Grant Budget
Narrative page. (See
http://grants.nih.gov/grants/funding/modular/modular.htm for sample
pages.) At the top of the page, enter the total Direct Costs requested
for each year. This is not a Form page.
Under Personnel, list all project personnel, including their names,
percent of effort, and roles on the project. No individual salary
information should be provided. However, the applicant should use the
NIH appropriation language salary cap and the NIH policy for graduate
student compensation in developing the budget request.
For Consortium/Contractual costs, provide an estimate of total costs
(Direct plus F&A) for each year, each rounded to the nearest $1,000.
List the individuals/organizations with whom consortium or contractual
arrangements have been made, the percent effort of all personnel, and
the role on the project. Indicate whether the collaborating
institution is foreign or domestic. The total cost for a
consortium/contractual arrangement is included in the overall requested
Modular Direct Cost amount. Include the letter of intent to establish
a consortium.
Provide an additional narrative budget justification for any variation
in the number of modules requested.
o BIOGRAPHICAL SKETCH - The Biographical Sketch provides information
used by reviewers in the assessment of each individual"s qualifications
for a specific role in the proposed project, as well as to evaluate the
overall qualifications of the research team. A biographical sketch is
required for all all personnel, following the instructions below. No
more than three pages may be used for each person. A sample
biographical sketch may be viewed at:
http://grants.nih.gov/grants/funding/modular/modular.htm
- Complete the educational block at the top of the Form page,
- List position(s) and any honors,
- Provide information, including overall goals and responsibilities, on
research projects ongoing or completed during the last three years, and
- List selected peer-reviewed publications with full citations.
o CHECKLIST - This page should be completed and submitted with the
application. If the F&A rate agreement has been established, indicate
the type of agreement and the date. All appropriate exclusions must be
applied in the calculation of the F&A costs for the initial budget
period and all future budget years.
The applicant should provide the name and phone number of the
individual to contact concerning fiscal and administrative issues if
additional information is necessary following the initial review.
The RFA label available in the PHS 398 (rev. 4/98) application form
must be affixed to the bottom of the face page of the application.
Type the RFA number on the label. Failure to use this label could
result in delayed processing of the application such that it may not
reach the review committee in time for review. In addition, the title
and number of this RFA must be typed in Item 2 on the face page of the
application form, and the YES box must be marked. The sample RFA label
available at:
http://grants.nih.gov/grants/funding/phs398/label-bk.pdf has been
modified to allow for this change. Please note this is in pdf format.
Submit a signed, typewritten original of the application, including the
Checklist, and three signed, photocopies in one package to:
CENTER FOR SCIENTIFIC REVIEW
NATIONAL INSTITUTES OF HEALTH
6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710
BETHESDA, MD 20892-7710
BETHESDA, MD 20817 (for express/courier service)
Applications must be received by the application receipt date listed in
the heading of this RFA. If an application is received after that
date, it will be returned to the applicant without review.
The Center for Scientific Research (CSR) will not accept any
application in response to this RFA that is essentially the same as one
currently pending initial review, unless the applicant withdraws the
pending application. The CSR will not accept any application that is
essentially the same as one already reviewed. This does not preclude
the submission of substantial revisions of applications already
reviewed, but such applications must include an introduction addressing
the previous critique.
REVIEW CONSIDERATIONS
Applications that are complete and responsive to the RFA will be
evaluated for scientific and technical merit by a peer review group
convened by CSR in accordance with the standard NIH peer review
procedures. As part of the initial merit review, all applications will
receive a written critique and may undergo a process in which only
those applications deemed to have the highest scientific merit,
generally the top half of the applications under review, will be
discussed, assigned a priority score, and receive a second level review
by the appropriate national advisory council or board.
REVIEW CRITERIA
The goals of NIH-supported research are to advance the understanding of
biological systems, improve the control of disease, and enhance health.
In the written comments, reviewers will be asked to discuss the
following aspects of the application to judge the likelihood that the
proposed research will have a substantial impact on the pursuit of
these goals. Each of these criteria will be addressed and considered
in assigning the overall score, weighting them as appropriate for each
application. Note that the application does not need to be strong in
all categories to be judged likely to have major scientific impact and
thus deserve a high priority score.
(1) Significance: Does this study address an important problem? If
the aims of the application are achieved, how will scientific knowledge
be advanced? What will be the effect of these studies on the concepts
or methods that drive this field?
(2) Approach: Are the conceptual framework, design, methods, and
analyses adequately developed, well-integrated, and appropriate to the
aims of the project? Does the applicant acknowledge potential problem
areas and consider alternative tactics?
(3) Innovation: Does the project employ novel concepts, approaches,
or method? Are the aims original and innovative? Does the project
challenge existing paradigms or develop new methodologies or
technologies?
(4) Investigator: Is the investigator appropriately trained and well
suited to carry out this work? Is the work proposed appropriate to the
experience level of the principal investigator and other researchers
(if any)?
(5) Environment: Does the scientific environment in which the work
will be done contribute to the probability of success? Do the proposed
experiments take advantage of unique features of the scientific
environment or employ useful collaborative arrangements? Is there
evidence of institutional support?
Additional Review Criteria
Since the objective of this proposal is to invite research applications
that may in whole or part consist of exploratory research rather than
proof of a well-established idea, innovation will be given high
priority in the review. Furthermore, there will be less emphasis on
preliminary data with respect to highly innovative proposals. Although
preliminary data should provide evidence that the applicant has the
means and understanding to carry out the proposed studies, preliminary
data does not necessarily have to provide a specific demonstration of
the hypotheses to be tested.
The following evaluation will be presented in an administrative note in
the Summary Statement, and will not factor into the numerical score:
- The adequacy of plans to make data available to other investigators
in a timely fashion. What is the likelihood that the methods and
materials generated in the project will be made widely available in a
timely fashion to the scientific community, given the proposed plan to
exercise (or not to exercise) intellectual property rights?
- The plan to share research resources and the plan to exercise (or not
exercise) intellectual property rights regarding patentable research
resources will be judged for appropriateness.
- The reasonableness of the proposed budget and duration in relation to
the proposed research.
- The adequacy of the proposed protection for animals and the
environment, to the extent they may be adversely affected by the
project proposed in the application.
Schedule:
Letter of Intent Receipt Date: March 11, 2001
Application Receipt Date: April 11, 2001
Peer Review Date: June/July 2001
Council Review: September 2001
Earliest Anticipated Award Date: September 30, 2001
AWARD CRITERIA
Award criteria that will be used to make award decisions include:
scientific merit as determined by peer review, adequacy of plans to
make widely available to the research community all research resources
developed during this project, adequacy of plans to exercise (or not
exercise) intellectual property rights while permitting wide
availability to the research community of patentable research resources
developed during this project, availability of funds, and programmatic
priorities.
INQUIRIES
Inquiries concerning this RFA are strongly encouraged. The opportunity
to clarify issues or questions from potential applicants is welcome.
Direct inquiries regarding programmatic issues to:
Jonathan D. Pollock, Ph.D.
Division of Neuroscience and Behavioral Research
National Institute on Drug Abuse/NIH
6001 Executive Boulevard, Room 4284, MSC 9555
Bethesda, MD 20892-9555
Phone: (301) 443-6300
Fax: (301) 594-6043
Email: jp183r@nih.gov
Anna M. McCormick, Ph.D.
Chief, Genetics and Cell Biology Branch
Genetics Program Director
Biology of Aging Program
National Institute on Aging/NIH
Gateway Building, Suite 2C231
Bethesda, MD 20892 (20814 for express deliveries)
Phone: (301) 496-6402
Fax: (301) 402-0010
Email: mccormia@exmur.nia.nih.gov
Dr. Thomas M. Johnson
Program Director
Scientific Programs Branch
National Institute on Deafness and Other Communication Disorders/NIH
Executive Plaza South-400C
6120 Executive Boulevard
Bethesda, MD 20892-7180
Phone: (301) 402-3461
Fax: (301) 402-6251
Email: tj65y@nih.gov
Rochelle K. Small, Ph.D.
Craniofacial Anomalies and Injuries Branch
National Institute of Dental and Craniofacial Research/NIH
Natcher Building, Room 4AN-24K
Bethesda, MD 20892
Phone: (301) 594-9898
Fax: (301) 480-8318
Email: rochelle.small@nih.gov
Peter A. Dudley, Ph.D.
Division of Extramural Research
National Eye Institute/NIH
Executive Plaza South, Suite 350
Bethesda, MD 20892-7164
Phone: (301) 496-0484
Fax: (301) 402-0528
Email: pad@nei.nih.gov
Bettie J. Graham, Ph.D.
Division of Extramural Research
National Human Genome Research Institute/NIH
Building 31, Room B2B07
Bethesda, MD 20892-2033
Phone: (301) 496-7531
Fax: (301) 480-2770
Email: bettie_graham@nih.gov
Dr. Sheryl Sato
Division of Diabetes, Endocrinology, and Metabolic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases/NIH
6707 Democracy Plaza, Room 6105
Bethesda, MD 20892-5460
Phone: (301) 594-8811
Fax: (301) 480-3503
Email: satos@extra.nddk.nih.gov
Hemin R. Chin, Ph.D.
Division of Neuroscience and Basic Behavioral Science
National Institute of Mental Health/NIH
6001 Executive Boulevard, Room 7190, MSC 9643
Bethesda, MD 20892-9643
Phone: (301) 443-1706
Fax: (301) 443-9890
Email: hemin@nih.gov
William J. Sharrock, Ph.D.
Musculoskeletal Diseases Branch
National Institute of Arthritis and Musculoskeletal and Skin Diseases
45 Center Drive, Natcher Building, Room 5AS-37A, MSC 6500
Bethesda, MD 20892-6500
Phone: (301) 594-5055
Fax: (301) 480-4543
Email: ws19h@nih.gov
Dr. Alison Deckhut
Basic Immunology Branch
Division of Allergy, Immunology and Transplantation
National Institute of Allergy and Infectious Diseases/NIH
6700-B Rockledge Drive, Room 5138, MSC 7640
Bethesda, MD 20892-7640
Phone: (301) 496-7551
Fax: (301) 402-2571
Email: adeckhut@niaid.nih.gov
Gabrielle Leblanc, Ph.D.
Neurogenetics
National Institute of Neurological Disorders and Stoke/NIH
6001 Executive Boulevard, Room 2133
Bethesda, MD 20892
Phone: (301) 496-5745
Fax: (301) 402-1501
Email: gl54h@nih.gov
Direct inquiries regarding fiscal matters to:
Gary Fleming, J.D., M.A.
Grants Management Branch
Office of Planning and Resource Management
National Institute on Drug Abuse/NIH
6001 Executive Boulevard, Room 3131, MSC 9541
Bethesda, MD 20892-9541
Phone: (301) 443-6710
Fax: (301) 594-6847
Email: gf6s@nih.gov
Ms. Linda Whipp
Grants and Contracts Management Office
National Institute on Aging/NIH
Gateway Building, Suite 2N212, MSC 9205
7201 Wisconsin Avenue
Bethesda, MD 20892-9205
Phone: (301) 496-1472
Fax: (301) 402-3672
Email: whippl@nia.nih.gov
Ms. Sara Stone
Chief, Grants Management Office
Division of Extramural Research
National Institute on Deafness and Other Communication Disorders/NIH
Executive Plaza South-400B
6120 Executive Boulevard
Bethesda, MD 20892-7180
Phone: (301) 402-0909
Fax: (301) 402-1758
Email: stones@nidcd.nih.gov
Mr. Martin Rubinstein
Grants Management Branch
National Institute of Dental and Craniofacial Research/NIH
45 Center Drive, Room 4AN-44
Bethesda, MD 20892-6402
Phone: (301) 594-4800
Fax: (301) 480-8301
Email: Martin.Rubinstein@nih.gov
Mr. William Darby
Grants Management Officer
National Eye Institute/NIH
Executive Plaza South, Suite 350
Bethesda, MD 20892-7164
Phone: (301) 496-5884
Fax: (301) 496-9997
Email: wwd@nei.nih.gov
Ms. Jean Cahill
Grants Administration Branch
National Human Genome Research Institute/NIH
Building 31, Room B2-B34
Bethesda, MD 20892-2031
Phone: (301) 402-0733
Fax: (301) 402-1951
Email: jc166o@nih.gov
Mr. George Tucker
Grants Management Branch
National Institute of Diabetes and Digestive and Kidney Diseases/NIH
6707 Democracy Boulevard, Rm. 654, MSC 5456
Bethesda, MD 20892-5456
Phone: (301) 594-8853
Fax: (301) 480-3504
Email: gt35v@nih.gov
Mr. Bruce L. Ringler
Grants Management Branch
National Institute of Mental Health/NIH
6001 Executive Boulevard, Room 6122, MSC 9605
Bethesda, MD 20892-9605
Phone: (301) 443-2811
Fax: (301) 443-6885
Email: bringler@mail.nih.gov
Ms. Melinda Nelson
Grants Management Officer
National Institute of Arthritis and Musculoskeletal and Skin
Diseases/NIH
45 Center Drive, Natcher Building, Room 5A49, MSC 6500
Bethesda MD 20892-6500
Phone: (301) 594-3535
Fax: (301) 480-5450
Email: mn23z@nih.gov
Ms. Pamela Fleming
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases/NIH
6700-B Rockledge Drive, Room 2119, MSC 7614
Bethesda, MD 20892-7614 (Regular Mail)
Bethesda, MD 20817 (Express Mail)
Phone: 301-402-6580
Fax: 301-493-0597
Email: pf49e@nih.gov
Ms. Tina Carlisle
Grants Management Branch
National Institute of Neurological Disorders and Stoke/NIH
6001 Executive Boulevard, Room 3290
Bethesda, MD 20892
Phone: (301) 496-9231
Fax: (301) 402-0219
Email: tc48k@nih.gov
AUTHORITY AND REGULATIONS
This program is described in the Catalog of Federal Domestic Assistance
No. 93.279 (NIDA), 93.173 (NIDCD), 93.867 (NEI), 93.242 (NIMH), 93.866
(NIA), 93.121 (NIDCR), 93.172 (NHGRI), 93.846 (NIAMS), 93.855 (NIAID),
93.853 (NINDS), and 93.847 (NIDDK). Awards are made under
authorization of Sections 301 and 405 of the Public Health Service Act
as amended (42 USC 241 and 284) and are administered under NIH grants
policies and Federal Regulations 42 CFR 52 and 45 CFR Part 74 and 92.
This program is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency review.
The PHS strongly encourages all grant recipients to provide a smoke-
free workplace and promote the non-use of all tobacco products. In
addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits
smoking in certain facilities (or in some cases, any portion of a
facility) in which regular or routine education, library, day care,
health care or early childhood development services are provided to
children. This is consistent with the PHS mission to protect and
advance the physical and mental health of the American people.
Weekly TOC for this Announcement
NIH Funding Opportunities and Notices
|
|
|
|
|
Department of Health
and Human Services (HHS)
|
|
|
|
|
NIH... Turning Discovery Into Health®
|
